Implication of CD35, CD21 and CD55 in Exudative Age-relat... | NCT01174407

Studies
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration

NCT01174407

Sponsor

Rudolf Foundation Clinic

Status

Unknown status

Last Update Posted

Aug 3, 2010Estimated

Enrollment

120Estimated

Phase

Not provided

Conditions

Age-Related Macular Degeneration

Interventions

cd 35, cd21, cd55

Countries

Austria

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Aug 2010

Overall Recruitment Status or Expanded Access Status

Unknown status

Last Known Status

Active, not recruiting

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Sep 2008

Primary Completion Date

Dec 2009Estimated

Completion Date

Aug 2010Estimated

First Submitted Date

Nov 19, 2008

First Submission Date that Met QC Criteria

Aug 2, 2010

First Posted Date

Aug 3, 2010Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Aug 2, 2010

Last Update Posted Date

Aug 3, 2010Estimated

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

120Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
cd35			Other: cd 35, cd21, cd55

Interventions

Name	Type	Description	Arm Group Labels	Other Names
cd 35, cd21, cd55	Other	Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient	cd35

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration		1 day

Secondary Outcomes

Measure	Description	Time Frame
expression rates of on AMD-patients and a healthy control group		1 year

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Man and women over 18 years old
Filled out informed consent
Diagnosis of non-exudative/ exudative age related macular degeneneration

Exclusion Criteria:

Inherited retinal diseases
Other acquired retinal/ macular
Missing informed consent

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

55 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

patients with exudative age-related macular degeneration, over 55

Sampling Method

Non-Probability Sample

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Rudolf Foundation Clinic		Vienna	State of Vienna	1030	Austria

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
21669404	Derived	Haas P, Aggermann T, Nagl M, Steindl-Kuscher K, Krugluger W, Binder S. Implication of CD21, CD35, and CD55 in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2011 Sep;152(3):396-399.e1. doi: 10.1016/j.ajo.2011.02.017. Epub 2011 Jun 12.

ID	Term
D012162	Retinal Degeneration
D012164	Retinal Diseases
D005128	Eye Diseases

ID	Term
D017464	Receptors, Complement 3d
D018958	CD55 Antigens

ID	Term
D011951	Receptors, Complement
D011971	Receptors, Immunologic
D011956	Receptors, Cell Surface
D008565	Membrane Proteins